Eventide Asset Management LLC Buys New Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Eventide Asset Management LLC bought a new position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 786,990 shares of the company's stock, valued at approximately $15,150,000. Eventide Asset Management LLC owned approximately 0.92% of Syndax Pharmaceuticals as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of SNDX. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new position in shares of Syndax Pharmaceuticals during the third quarter worth about $15,165,000. First Turn Management LLC purchased a new position in Syndax Pharmaceuticals in the 2nd quarter worth approximately $13,147,000. Vanguard Group Inc. increased its holdings in shares of Syndax Pharmaceuticals by 13.6% in the 1st quarter. Vanguard Group Inc. now owns 4,926,984 shares of the company's stock worth $117,262,000 after buying an additional 591,631 shares during the last quarter. Sofinnova Investments Inc. raised its position in shares of Syndax Pharmaceuticals by 33.9% during the 2nd quarter. Sofinnova Investments Inc. now owns 2,153,669 shares of the company's stock valued at $44,215,000 after buying an additional 545,129 shares in the last quarter. Finally, Millennium Management LLC lifted its holdings in shares of Syndax Pharmaceuticals by 56.3% during the 2nd quarter. Millennium Management LLC now owns 1,065,508 shares of the company's stock worth $21,875,000 after acquiring an additional 383,634 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on SNDX. UBS Group started coverage on Syndax Pharmaceuticals in a research note on Thursday, October 24th. They issued a "buy" rating and a $37.00 target price on the stock. HC Wainwright increased their price objective on Syndax Pharmaceuticals from $49.00 to $51.00 and gave the company a "buy" rating in a research report on Monday, November 18th. Citigroup raised their price objective on Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a "buy" rating in a report on Tuesday, November 19th. JPMorgan Chase & Co. upped their target price on Syndax Pharmaceuticals from $33.00 to $38.00 and gave the stock an "overweight" rating in a research note on Thursday, November 21st. Finally, Barclays increased their price target on shares of Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an "overweight" rating in a research report on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $37.64.

Syndax Pharmaceuticals Stock Performance

Shares of NASDAQ SNDX traded up $0.21 during mid-day trading on Friday, hitting $16.72. The stock had a trading volume of 962,452 shares, compared to its average volume of 1,170,396. Syndax Pharmaceuticals, Inc. has a 1 year low of $15.00 and a 1 year high of $25.34. The firm has a market cap of $1.43 billion, a P/E ratio of -4.61 and a beta of 0.92. The business has a 50 day moving average price of $18.44 and a two-hundred day moving average price of $19.80.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its earnings results on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, topping analysts' consensus estimates of ($1.13) by $0.15. The firm had revenue of $12.50 million for the quarter, compared to the consensus estimate of $9.16 million. During the same quarter in the previous year, the business posted ($0.73) EPS. Equities research analysts predict that Syndax Pharmaceuticals, Inc. will post -2.39 EPS for the current fiscal year.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).